Aerie Pharmaceuticals (AERI) : Wednesdays money flow indicated an uptick to downtick ratio was at 1.15. The total value of inflow transactions on upticks was $8.96 million, whereas, the total value of outflow trades on downticks was $7.77 million. The total money flow was $1.19 million, which shows a mild bullish bias. The total money flow into the stock in block trades was $0.15 million. The total value of the trades done on upticks was $0.56 million. Downticks saw transactions worth $0.41 million. The total uptick to downtick ratio stood at 1.35, mildly in favor of the bulls. Aerie Pharmaceuticals (AERI) was trading with a -3.19% change over previous days close. It fell $1.3 during the day and reached $39.42. The stock was 0.9% compared to the previous weeks close.
Shares of Aerie Pharmaceuticals, Inc. rose by 0.77% in the last five trading days and 106.16% for the last 4 weeks. Aerie Pharmaceuticals, Inc. is up 117.5% in the last 3-month period. Year-to-Date the stock performance stands at 60.78%.
Aerie Pharmaceuticals (AERI) : The consensus on Aerie Pharmaceuticals (AERI) based on 8 analyst recommendation on the company stock is 1.25, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 6 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 2 analyst believes that the stock is a Buy, which can produce decent returns in the future.
Aerie Pharmaceuticals (NASDAQ:AERI): stock was range-bound between the intraday low of $38.02 and the intraday high of $40.6 after having opened at $40.42 on Wednesdays session. The stock finally closed in the red at $40.42, a loss of -3.86%. The stock remained in the red for the whole trading day. The total traded volume was 1,057,894 shares. The stock failed to cross $40.6 in Wednesdays trading. The stocks closing price on Thursday was $40.72.
Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Companys primary product candidates, triple-action Rhopressa and quadruple-action Roclatan, are once-daily eye drops. The Companys product candidate, once-daily, quadruple-action Roclatan, is a single drop fixed-dose combination of Rhopressa and latanoprost. Rhopressa inhibits Rho Kinase (ROCK) and the norepinephrine transporter (NET), which are both biochemical targets for lowering intraocular pressure (IOP). The Companys Rhopressa product candidate was in Phase III stage of development. The Company has completed the Roclatan Phase IIb clinical trial. The Company is also in the preclinical development stage with AR-13533, its second-generation ROCK/NET inhibitor.